Goldman Sachs analyst Matthew Sykes upgraded Sotera Health (SHC) to Buy from Neutral with a price target of $17, up from $14, representing 36% upside. The company’s “durable” business model with exposure to commercial pharmaceutical and medical devices has become “much more attractive” in the current environment given increased macro-related uncertainty, the analyst tells investors in a research note. The firm says Sotera is also well positioned in the tariff-related uncertainty, given its service based model in its Sterigenics and Nelson Labs businesses and the exemption of Nelson Cobalt related products from tariffs according to the U.S. annex.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health Q1 2025 Earnings Call Highlights Growth and Challenges
- Sotera Health Reports Mixed Q1 2025 Results
- Sotera Health price target raised to $15 from $12 at Barclays
- Sotera Health reports Q1 adjusted EPS 14c, consensus 12c
- Sotera Health reaffirms FY25 adjusted EPS view 70c-76c, consensus 74c